Alzheimer's Disease Clinical Trial
Official title:
Phase 4 Study of a Reminiscence Program to Improve Quality of Life of Alzheimer's Disease Long Term Care Residents Using a Randomized Controlled Trial
The effectiveness of reminiscence for dementia has been claimed as an effective tool, but scientific validation and systematic assessment of this method is needed. Materials and Methods: A randomized controlled trial (RCT) was conducted to search whether a reminiscence program is associated with improvement of quality of life of demented long term care residents. The trial had three arms: interventional, comparison and control. The reminiscence program was modeled within a life-story approach, while comparison group received informal counseling to control for changes in quality of life resulting from social contacts. The Social Engagement Scale (SES) and Self-rated Quality of Life Index (SRQoL) were the outcome measures. The results were examined at baseline (T0), twelve weeks (T1), and 6 months (T2) after intervention. The sample had 135 subjects [intervention group (N=45), comparison group (N=45) and control group (N=45)].
A total number of 135 residents will be recruited from two private funded long term nursing
homes, which shared equal structural and functional characteristics. Subjects were randomly
assigned to one of the three groups (intervention, comparison and control). The subjects
admitted for the study are diagnosed as having Alzheimer's disease according to the DSM-IV
are able to communicate with a Holden Communication Scale scores>25 and have a Folstein
mental Exam score above 10. Exclusion criteria are active major psychiatric disorders
(schizophrenia, major affective disorders); acute or unstable chronic medical conditions
including cardiac or lung diseases; blindness and deafness, even with hearing aids, both
assessed with the RAI blindness and deafness scales.
Power and sample size calculation. Sample size will be estimated taking into account that
the study had to test a null hypothesis whether the different participating groups were
similar or different. It is assumed that a significant change in dementia nursing home
resident quality of life (QoL) from baseline would be of half a standard deviation, which
equals to 3 points, as found in a previous longitudinal study10. With this predicted effect
size of QoL, a power of 80% and a type I error for independent groups of 0.01, the estimated
sample size was 143 participants in the total study population.
Methods and materials The intervention was designed as an individual treatment condition in
which each participating subject received 24 bi-weekly sessions of reminiscence therapy,
lasting one hour each one, over a period of 12 weeks. The latter refers to the use of
images, sentences or memorabilia which help to focus on specific segments of the life
history of an individual, and stimulates the emergence of affect-laden personal recalls,
which are later verbalized in the context of guided conversations. The term story life is
intended to highlight samples of meaningful events of the subject's life rather than a
historically structured biography. The control group was administered counseling and
informal social contacts in bi-weekly sessions of one hour, but they didn't participate in
reminiscence sessions. This was intended to rule out the possibility that improvement in
quality of life was due only to attention received and social stimulation. The comparison
group received unstructured social contacts, again in bi-weekly sessions of one hour each
one. Remaining features in the design of the three arms were similar with the only exception
being the structured reminiscence program participation. The study was approved by the local
Ethics Review Committee. This study adopted a single-blinded, parallel-group (one
intervention, one comparison, and one control [no-intervention] group) design to address the
following hypothesis: a) residents with Alzheimer's disease submitted to a reminiscence
program intervention will show a better quality of life as a consequence of greater sense of
self identity regarding groups with no specific therapeutic intervention, b) this quality of
life improvement will be sustained beyond actual therapeutic intervention, due to
consolidation of self identity and the reinforcing effects of increased competence, efficacy
and personal involvement in everyday activities, associated with higher sense of self.
Demographic and clinical data of residents, including age, gender, marital status, level of
education, religion, length of dementia, length of stay in the nursing home, associated
medical problems, Mini-mental State Examination (MMSE) score, Cognitive Performance Scale
level (CPS)15, ability to communicate, functional abilities, use of psychotropic
medications, fitness programs, physical restrictions, number of visits per month from
families and friends, and caregiver burden with the Burden Interview (short version ) will
be collected. The severity of dementia will be staged with the CDR. The functional
performance of the residents will be assessed using an index of physical function for level
of independence in eating, dressing, toileting, transferring, and walking by using magnitude
estimation weights. Each level of disability on each activity is given a weight, rather than
a simple count. The resulting score ranges from 0 (no limitation) to 3.77 (completely
disabled on five activities of daily living) and has ratio scale properties. To assess
physical restraints the investigators used an indicator of daily use of full bed rails,
trunk or limb restraints, or a chair that prevents rising. Physical restraints are not an
aspect of the individual resident, but they are a clinical care process that is modifiable
by the facility. Restraint use is considered an indicator of poor quality of care and an
infringement on individual autonomy that diminishes QOL. Cognitive performance was assessed
with the CPS. This is a clinically derived scale to predict MMSE and Test for Severe
Impairment scores18. While MMSE has a floor effect with minimal scores suggesting
questionable validity for more cognitively impaired elders, the TSI achieves meaningful
variations, minimizes reliance on language skills and permitting subjects to answer
correctly through nonverbal as well as verbal responses. Is composed of twenty-one items
covering six cognitive areas: well-learned motor performance, language comprehension,
language production, immediate and delayed memory, conceptualization, and general knowledge.
The best score is 24, the lower is zero. For persons with an MMSE score of 11 or more, they
will have TSI scores of 22 or higher. The CPS is composed by five items: 1-short-term
memory, 2-cognitive skills for daily decision making, 3-coma (or persistent vegetative
state), 4-making self understood and 5-eating. The scale has an average inter-rater
reliability of 0.85 and a sensibility of 0.92 and specificity of 0.87. The CPS classifies
residents into seven cognitive performance levels, from level 0 (Intact) with a mean MMSE
score of 25, to Level 6 (Very Severe Impairment) with a near to zero. CPS Levels 2 and 3
(Mild and Moderate Impairment) corresponds to a MMSE score of 10 or higher, averaging 10.3
and 13.8, and to a TPI of 21 (SD=3.6). The Social Engagement Scale19 rates the resident
status during the last seven days in areas such as ease interaction with others and doing
planned or structured activities. Each item is ranked on a binary basis, as yes (1) or no
(0) by the caregiver. The highest score is 6 and the lowest is 0. It has high internal
consistency (intra-class correlation: 0.51-0.64), and the items shows reliability across
different groups of residents with variable levels of functional and cognitive status. The
resident self-reported SRQoL was measured using a multidimensional self-report instrument20.
It measures 11 dimensions of QOL relative to a resident's experience: comfort, functional
competence, privacy, dignity, autonomy, meaningful activities, relationships, food
enjoyment, spiritual well-being, security, and individuality. Each dimension is scored on a
4-point Likert scale, with 4 meaning often, 3 sometimes, 2 rarely and 1 never. Residents
unable to use the 4-point scale could answer ''generally yes'' or ''generally no.'' These
responses are scored as 3.8 and 1.5, respectively, based on a z score approximation method.
Reliability scores range between Cronbach's alpha values of 0.78 and 0.8521. Anxiety will be
assessed using the Rating of Anxiety in Dementia (RAID): an 18-item scale with scores >11
indicating significant anxiety symptoms. Depression will be ruled out using the Minimum Data
Set Depression Rating Scale. This is a standardized screening instrument for detecting
depression among nursing home residents. Its comprises seven core Minimum Data Set mood
items with a sensibility of 69% and a sensitivity of 91%, and a Cronbach α measure of
internal consistency of 0,75. It has a score range of 0-14 with a cut-off point of 3. The
Burden Interview short version (ZBI)24 will be used to measure the strain and burden
experienced by caregivers on a 12 items scale, each one is scored on a 5 point Likert scale
from 0 (never) to 4 (always). It has a range of results from 0 to 48, a Cronbach's alpha of
0.88, and a cutoff score of 17. Well being of residents will be assessed using the
Well-being/Ill-being Scale (WIB)25 which includes positive components such as "being able to
express wishes in an acceptable way," "bodily relaxation," and "creative self expression"
(such as singing, dancing or painting), and negative ones such as "unattended sadness or
grief," "sustained anger" or "anxiety." The WIB scale rates each category of behavior
observed every five minutes for a minimum of six hours. After five minutes, the rater
quantifies the nature of the observed behavior category by assigning a WIB value to it. The
six-point WIB scale ranges from very negative to very positive (−5, −3, −1, +1, +3, +5).
Values will be calculated at the end of the observation period to extract a mean score.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02309723 -
How Beta-amyloid Imagining Influences Clinician Diagnosis and Management of Hypothetical Patients With Cognitive Complaints
|
N/A |